| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary molecular target of (E)-Crotylbarbital is the GABA-A receptor, a ligand-gated ion channel that mediates inhibitory neurotransmission in the central nervous system. Barbiturates like (E)-Crotylbarbital bind to the GABA-A receptor and enhance the inhibitory effects of GABA, leading to sedation, hypnosis, and anticonvulsant effects.
|
|---|---|
| ln Vitro |
In vitro, (E)-Crotylbarbital enhances GABA-A receptor-mediated chloride currents in cultured neurons. It is used in electrophysiology assays to study barbiturate modulation of GABA-A receptors. The compound's sedative and anticonvulsant effects are characterized in various in vitro models.
|
| ln Vivo |
In vivo, (E)-Crotylbarbital exhibits sedative, hypnotic, and anticonvulsant effects in animal models. It is used for the research of insomnia and seizure disorders. Barbiturates like (E)-Crotylbarbital have been largely replaced by safer alternatives due to their narrow therapeutic index and high abuse potential.
|
| Enzyme Assay |
For in vitro GABA-A receptor binding assays, membrane preparations from rat brain are incubated with a radiolabeled GABA-A receptor ligand (e.g., [3H]-muscimol or [3H]-flunitrazepam) and varying concentrations of (E)-Crotylbarbital. The assay is performed in an appropriate buffer at 4°C. Bound radioactivity is separated by filtration and quantified.
|
| Cell Assay |
In vitro cell experiments for (E)-Crotylbarbital employ primary neuronal cultures or neuroblastoma cells. Cells are treated with (E)-Crotylbarbital at concentrations ranging from 0.1 to 100 μM. GABA-induced chloride currents are measured by patch-clamp electrophysiology. Cytotoxicity is assessed by MTT assay.
|
| Animal Protocol |
In vivo animal protocols for (E)-Crotylbarbital use mouse or rat models. The compound is administered by intraperitoneal or oral routes at doses ranging from 1 to 50 mg/kg. Sedative/hypnotic effects are assessed by measuring sleep time, and anticonvulsant effects are assessed using the maximal electroshock or pentylenetetrazol seizure models.
|
| Additional Infomation |
Crotarbital is the parent compound for which no isomer has been specified.
|
| Molecular Formula |
C₁₀H₁₄N₂O₃
|
|---|---|
| Molecular Weight |
210.23
|
| Exact Mass |
210.1
|
| CAS # |
28360-89-6
|
| Related CAS # |
2933-25-7 (hydrochloride salt)
|
| PubChem CID |
5364821
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.372
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
15
|
| Complexity |
314
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(NC(=O)C(CC)(C/C=C/C)C(=O)N1)=O
|
| InChi Key |
KNMOHCLEINXVBG-HWKANZROSA-N
|
| InChi Code |
InChI=1S/C10H14N2O3/c1-3-5-6-10(4-2)7(13)11-9(15)12-8(10)14/h3,5H,4,6H2,1-2H3,(H2,11,12,13,14,15)/b5-3+
|
| Chemical Name |
5-[(E)-but-2-enyl]-5-ethyl-1,3-diazinane-2,4,6-trione
|
| Synonyms |
(E)Crotylbarbital; (E) Crotylbarbital
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7567 mL | 23.7835 mL | 47.5670 mL | |
| 5 mM | 0.9513 mL | 4.7567 mL | 9.5134 mL | |
| 10 mM | 0.4757 mL | 2.3783 mL | 4.7567 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
